Japan – Eisai Showcases Oncology Portfolio and Pipeline at ASCO 2024
Eisai Showcases Oncology Portfolio and Pipeline at ASCO 2024
Eisai Co., Ltd. announced today the presentation of research across multiple types of cancer from its oncology portfolio and pipeline during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO24), which is taking place virtually and in-person in Chicago, Illinois from May 31 to June 4.
Notable data includes an oral presentation on biomarker analyses from the pivotal Phase 3 CLEAR (Study 307)/KEYNOTE-581 trial (NCT02811861(New Window)), which evaluated lenvatinib (LENVIMA®) plus pembrolizumab (KEYTRUDA®) versus sunitinib for the first-line treatment of patients with advanced renal cell carcinoma (Abstract #4504). An analysis of patterns of disease progression and subsequent therapy from this trial will also be presented in a poster presentation (Abstract #4524).
“At Eisai, we let the science drive us to new approaches that accelerate progress in oncology, while also remaining grounded in our human health care concept that reinforces our commitment to prioritize the needs of patients and families impacted by a cancer diagnosis,” said Dr. Takashi Owa, Chief Scientific Officer, Senior Vice President, Eisai Co., Ltd. “With this in mind, we look forward to sharing research that provides further insight into the role of lenvatinib plus pembrolizumab as a first-line standard of care option in advanced renal cell carcinoma, as well as research that explores various modalities in our pipeline for the potential treatment of advanced diseases with the goal of improving patients’ lives.”
Other key research of note from Eisai’s pipeline include an oral presentation of Phase 3 data from the JBCRG-M06/EMERALD study in Japan evaluating trastuzumab and pertuzumab in combination with Eisai’s eribulin mesylate or a taxane in patients with HER2-positive, locally advanced or metastatic breast cancer (NCT03264547(New Window); Abstract #1007).
Additional pipeline research to be presented in poster sessions include an overview of a Phase 2 study of BB-1701, an antibody drug conjugate targeting HER2, in previously treated patients with HER2-positive or HER2-low unresectable or metastatic breast cancer (NCT06188559(New Window); Abstract #TPS1122), findings from a Phase 1b trial of tasurgratinib (development code: E7090) with or without endocrine therapies for patients with ER-positive, HER2−negative recurrent/metastatic breast cancer after receiving a CDK4/6 inhibitor (NCT04572295(New Window); Abstract #3103), as well as the dose-expansion part of a Phase 1b global study of E7386 in combination with lenvatinib in patients with hepatocellular carcinoma and other solid tumors including endometrial cancer (NCT04008797(New Window); Abstract #TPS3169).
This release discusses investigational compounds and investigational uses for FDA-approved products. It is not intended to convey conclusions about efficacy and safety. There is no guarantee that any investigational compounds or investigational uses of FDA-approved products will successfully complete clinical development or gain FDA approval.
The full list of Eisai presentations can be viewed here: www.eisai.com/news/2024/news202435.htmlIn March 2018, Eisai and Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside the United States and Canada), through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of lenvatinib, both as monotherapy and in combination with Merck’s anti-PD-1 therapy pembrolizumab. Eisai and Merck are studying the lenvatinib plus pembrolizumab combination through the LEAP (LEnvatinib And Pembrolizumab) clinical program in various tumor types across more than multiple clinical trials.
In May 2023, Eisai entered into a joint development agreement with Bliss Biopharmaceutical (Hangzhou) Co., Ltd. (Headquarters: Zhejiang Province, China, “BlissBio”), for BB-1701, a HER2-targeting antibody drug conjugate (ADC), with option rights for a strategic collaboration. Eisai and BlissBio are currently investigating BB-1701 in a Phase 2 clinical trial in Japan and the United States for breast cancer and a Phase 1/2 clinical trial in the United States and China for HER2-expressing solid tumors.
1. Eisai’s Focus on Cancer
Eisai acknowledges “Oncology” as one of its key strategic areas, and will continue to focus on the discovery and development of anti-cancer drugs within drug discovery domains including “tumor microenvironment”, “proteostasis disruption”, “cell linage and cell differentiation”, and “inflammation, hypoxia, oxidative stress and cell senescence” under the Deep Human Biology Learning (DHBL) drug discovery and development organization. Eisai aspires to discover innovative new drugs with new targets and mechanisms of action from these domains with the aim of contributing to the cure of cancers.
(1) KEYTRUDA is a registered trademark of Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
(2) E7386 is created through collaboration research between Eisai and PRISM BioLab Co., Ltd. (Headquarters: Kanagawa)
(3) The presentation with TPS (Trial in Progress Submission) attached to the abstract number indicates that the study is in the intermediate stage, and the presentation does not report the final study results.
Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120
Academic Labs Showcases Innovative Courses, Attracting Key Investor with Community-Powered Model
Academic Labs, an innovative new AI and blockchain education platform, has unveiled its first set of demo courses focusing on highly relevant tech topics like layer 2 blockchain, ChatGPT, and crypto investing strategies. These cutting-edge courses showcase Academic Labs’ unique methodology of incentivizing content creators and delivering fun, gamified learning experiences.
Academic Labs was conceptualized and founded by Kingston Kwek, a well-regarded crypto and tech entrepreneur from Singapore, for which he is also the owner and the chief visionary officer (CVO). In this interview, Kwek explained why Academic Labs’ bottoms-up, community-driven approach makes it stand out in the nascent world of blockchain education.
“Academic Labs is a unique first-mover Web 3 social experiment in the use of blockchain in education,” said Kwek. “It will address the current lack of educational materials and platforms for AI and crypto education based on Web 3 technologies.”
Kwek highlighted that by rewarding content creators with native Acad tokens, Academic Labs can crowdsource high-quality, localized materials tailored to individual markets. “We have started the ball rolling through our first three videos to set the standards for the subsequent videos,” he said.
According to Kwek, these demo courses on layer 2 blockchain, ChatGPT, and crypto investing strategies provide sophisticated learners a taste of Academic Labs’ potential. By incentivizing the community to create more in-depth follow-up courses, the platform can scale up to offer hundreds of short, engaging videos on cutting-edge topics.
“As the scale and sub-topics of the videos expands, Acad will eventually cross-paths with more crypto projects and crypto fund managers and exchanges, which will gave Acad many more potential joint venture projects with other crypto projects and crypto fund managers and exchanges, to add to the value of Acad and its business partners,” said Kwek.
The three demo videos cover layer 2 blockchain technology, ChatGPT, and crypto investing strategies. The layer 2 blockchain video provides an overview of how layer 2 solutions can improve blockchain performance for applications like crypto payments, NFTs, and gaming. The ChatGPT video explains the AI’s advanced conversational abilities, based on reinforcement learning algorithms that mimic human responses. And the crypto investing video outlines key factors like technology, tokenomics, and community sentiment to evaluate the investment potential of new cryptocurrencies.
While simple overviews, Kwek emphasized these demo videos are just a starting point to showcase Academic Labs’ methodology and set quality standards for future content. As the library expands, the topics covered can become more specialized and in-depth, creating hundreds of focused, engaging 3-10 minute videos.
For example, future videos could provide laser-focused dives into using layer 2 solutions specifically for gaming or NFT projects. Or give in-depth looks at specific NFT communities like the Bored Ape Yacht Club. This ever-growing, crowdsourced library will establish Academic Labs as a go-to destination for short-form education on cutting-edge AI, crypto, and blockchain topics.
Strategic angel investors like Kwek also highlight the promising vision behind Academic Labs. “As the scale and sub-topics of the videos expands, Acad will eventually cross-paths with more crypto projects and crypto fund managers and exchanges, which will gave Acad many more potential joint venture projects with other crypto projects and crypto fund managers and exchanges, to add to the value of Acad and its business partners,” he explained.
As an influential Singaporean business leader, Kwek’s backing signals strong confidence in Academic Lab’s community-powered model to revolutionize blockchain education. The platform’s incentives will empower legions of content creators worldwide to develop localized materials that perfectly meet demands in niche markets.
This crowdsourced, collaborative approach allows Academic Labs to rapidly scale up and cross-promote with major players across the crypto space. Joint ventures with other projects, exchanges, and investors will create a positive feedback loop, enhancing the value of the Acad token and the earning potential for content creators on the platform.
With its laser focus on highly relevant subject matter, innovative model to crowdsource quality localized content, and support of key strategic investors, Academic Labs aims to become the premier destination for short-form, cutting-edge education on AI, crypto, and blockchain technologies. As Kwek summarized, the platform represents “one of the few exciting altcoin projects in the market” and has major potential in the next bull cycle.
About Academic Labs
Academic Labs is an innovative company at the forefront of educational transformation. With a focus on harnessing the power of blockchain technology, AI, and Non-Fungible Tokens (NFTs), Academic Labs has developed a groundbreaking educational platform that aims to make learning more engaging, effective, and accessible for everyone.
Social Links
Telegram Group: https://web.telegram.org/k/#@academic_labs
Telegram Channel: https://web.telegram.org/k/#@academiclabs
Linkedin: https://www.linkedin.com/company/academic-labs/
X: https://x.com/Acad_Labs
Linktree: https://linktr.ee/academic_labs
Media Contact
Terry Tan, Academic Labs
Email: Terry@academic-labs.org
Website: https://academic-labs.org
Topic: Press release summary
BYD | RIDE Showcases Battery-Electric Link Transit Bus at WSTA
BYD | RIDE showed off its world-renowned battery-electric transit solution this week at the 47th Annual Washington State Transit Association (WSTA) Public Transportation Conference, Vendor Expo and State “Roadeo.”
On display was a K8M, one of 11 BYD buses recently added to the Link Transit fleet in Wenatchee, Washington. Link Transit serves Chelan and Douglas counties, operating twenty-three buses in all.
“We are very grateful for our partnership with Link Transit and for their continued support,” said Patrick Duan, BYD’s Senior Vice President and RIDE Co-CEO. “WSTA was a great opportunity for us to showcase how Link Transit is helping improve air quality by providing its passengers with clean transportation alternatives.”
The K8M, which was displayed at WSTA, can seat up to 32 passengers, has a working range of up to 196 miles, and is equipped with the industry’s safest battery. The 35’ bus gave guests an opportunity to see how BYD | RIDE is redefining the future of transportation with its innovative technology.
The buses are purpose-built by members of the Sheet Metal, Air, Rail and Transportation (SMART) Workers Union, Local 105, at the BYD Coach and Bus Facility located in Lancaster, CA. BYD is the only battery-electric bus manufacturer that has both a unionized workforce and a Community BenefitsAgreement, which sets goals for hiring veterans, single parents, second BYD is the only battery-electric bus manufacturer that has both a unionized workforce and a Community Benefits chance citizens, and others facing hurdles in obtaining manufacturing employment.
About BYD:
BYD, which stands for Build Your Dreams, is the world’s leading battery- electric bus manufacturer with over 80,000 vehicles on the road globally, and more than 1,000 vehicles on the road or in production in the United States. BYD is creating hundreds of American jobs, making battery-electric buses that are helping to clean our air while improving efficiency and the bottom line for our customers. Follow BYD on Facebook, Twitter, YouTube and Instagram.
Contact:
Alexa Trujillo | BYD Community Relations Associate +1 (661) 940-3250 ext. 72530 alexa.trujillo@byd.com
BYD
Kelsey Cone
661-436-0513
byd.com
Contact
Categories
- Transportation
ReadersMagnet Showcases Ilyse Rothman’s Children’s Book “I Already Am!” at the 2023 LibLearnX
Ilyse Rothmans childrens book is wrapped in self-concept awareness and love.
San Diego, California, USA – WEBWIRE – Thursday, March 2, 2023
ReadersMagnet displayed Ilyse Rothmans “I Already Am!” at their exhibit booth for 2023 LibLearnX: The Library Learning Experience (LLX) from January 27 to 30, 2023.
ReadersMagnet, a self-publishing company, displayed Ilyse Rothmans book I Already Am! at the 2023 LibLearnX: The Library Learning Experience (LLX). LibLearnX occurred on 27-30, 2023, at the Ernest N. Morial Convention Center in New Orleans, Louisiana. Library professionals and authors were among the attendees who participated in the four-day learning conference. Author Ilyse Rothman also attended the event.
Her childrens book I Already Am! will remind its young readers that they can be whatever they desire, regardless of age. Said Ilyse about her book, I Already Am! is here to remind us that WE ALREADY ARE everything we thing we need to grow to be!
As children turn the pages of the book, they will be cheered by the vivid and colorful images. Ilyse dedicates I Already Am! to kids and everyones inner child. It aims to empower kids to realize their potential is a singular paradigm shifter that can result in a happy and meaningful life. The book by Ilyse is fantastic for parents and teachers who wish to inspire children to be their best selves. Participants of the 2023 LibLearnX, especially parents and early education teachers, are pleased to know and read Ilyse Rothmans book. It is designed to touch the hearts and nurturing power of children and adults reading the book.
Interested readers may grab a copy of Ilyse Rothmans I Already Am! now available on Amazon and Barnes & Noble. Learn more about Ilyse and her works by visiting her website: http://www.ilyserothman.com/.
I Already Am!
Author | Ilyse Rothman
Genre | Childrens Book
Publisher | AuthorHouse
Published date | March 4, 2014
Author
Ilyse Rothman is the founder of The Flip Your Script Formula by YUMLife. Those who know Ilyse describe her as a master due to her uncanny ability to enlighten people on how to identify, release, and rewrite the chapters of their lives rooted in struggle. She can do it while making sure that people grow a life they love and all part of themselves.
Her larger-than-life approach to living began after her recovery from an autoimmune disease that left her paralyzed for months. While recovering, Ilyse recognized the tremendous power of belief. Her journey gave her countless recognition from organizations and publications such as Best of New York, A & E TV, and Time Out New York.
Ilyse Rothman actively works by helping others gain significant insights and tools in understanding a deep mind and body connection.
WEBWIRE – Sunday, January 1, 2023
The LANG Companies, Inc. is excited to announce the launch of new Luxe Christmas Cards and Luxe Puzzles.
The new Luxe Christmas Cards are elegantly crafted cards featuring various, unique details including foil accents, glitter and 3D die-cut tip-on. Each set contains 8 cards & 8 envelopes on linen embossed paper stock adorned with full-color artwork inside and out.
LANG Luxe 500 Piece Puzzles offer an upscale finish to a classic product category. With a soft touch finish, decorative storage box, and foil or glitter accents, you can both see and feel the quality of these new puzzles.
LANGs Luxe Christmas Cards are scheduled to be available July 2023. LANG Luxe Puzzles are scheduled to be available April 2023. For more information on new LANG products, including the 2022 LANG product catalog, please visit B2B.LANG.com
###
About LANG
LANG Showcases New Product Category: Luxe Christmas Cards & Luxe Puzzles
The LANG Companies, Inc. is a division of IG Design Group Americas Inc. Since 1982, the LANG Companies has been an industry leader in producing art and design-driven gift and specialty products, and sports licensed goods including calendars, drinkware, and stationery. Our diversified product portfolio is marketed under several widely recognized, company-owned brands: LANG, Wells Street by LANG, Artisan by LANG, SKYZ by LANG and Turner Licensing. Each unique brand has a long-standing heritage, is differentiated in the marketplace and dominantAds
